DuPont Delivers Strong 3Q Earnings
Today, DuPont reported third quarter 2010 earnings per share (EPS) and increased 2010 guidance, based on continued global sales growth in all segments and all regions.
DuPont’s third-quarter 2010 reported earnings per share were $.40, compared to $.45 in third quarter 2009, despite a $.13 decline in Pharmaceuticals income related to patent expirations.
“I am proud of our business teams’ performance this quarter, with segment pre-tax earnings up 33% excluding Pharmaceuticals income,” said DuPont Chair and CEO Ellen Kullman. “DuPont’s market focus and science-based innovations said. “This quarter’s results were complemented by ongoing productivity improvements and rigorous cost management that contributed to profitable growth.”
The table below shows year-over-year earnings per share (EPS) variances for the third quarter.
|
|
|
|
|||
EPS ANALYSIS |
||||||
|
|
|
|
|||
|
|
3Q |
|
|||
|
|
|
|
|||
EPS- 2009 |
|
$.45 |
|
|||
|
|
|
|
|||
Local prices |
|
.29 |
|
|||
Variable cost* |
|
(.29) |
|
|||
Volume |
|
.31 |
|
|||
Fixed cost* |
|
(.18) |
|
|||
Currency |
|
(.02) |
|
|||
Other (includes Pharmaceuticals)** |
|
(.10) |
|
|||
Tax |
|
(.06) |
|
|||
|
|
|
|
|||
EPS- 2010 |
|
$.40 |
|
|||
|
|
|
|
|||
* Fixed and variable costs exclude volume & currency impacts ** Includes $(.13) lower Pharmaceuticals income |
||||||
SOURCE
